EMEA-002536-PIP01-18-M01

Key facts

Active substance
Lebrikizumab
Therapeutic area
Dermatology
Decision number
P/0286/2021
PIP number
EMEA-002536-PIP01-18-M01
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of atopic dermatitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Dermira Inc.

Tel.: +1 8773375552
E-mail: Pediatrics@dermira.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating
Average
1 rating